Sanofi: Dupixent Significantly Reduced COPD Exacerbations in Second Positive Phase 3

 NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL), confirming results from the landmark BOREAS pivotal trial

Dupixent rapidly and significantly improved lung function (139 mL in FEV1) compared to placebo (57 mL in FEV1) at 12 weeks

Supplemental BLA submission planned by end of 2023

Approximately 300,000 people in the United States live with uncontrolled COPD with evidence of type 2 inflammation; no new treatment approaches approved for more than a decade

https://finance.yahoo.com/news/dupixent-dupilumab-significantly-reduced-copd-063000391.html